Which of the following anticancer drugs are competitive inhibitors of tyrosine kinase ?
**Core Concept**
Tyrosine kinase inhibitors (TKIs) are a class of anticancer drugs that target the enzyme tyrosine kinase, which is involved in the signaling pathways that regulate cell growth and division. By inhibiting tyrosine kinase, TKIs can prevent cancer cells from growing and dividing uncontrollably.
**Why the Correct Answer is Right**
The correct answer is a type of TKI that works by competing with ATP (adenosine triphosphate) for binding to the tyrosine kinase enzyme, thereby preventing the enzyme from phosphorylating its substrate. This results in the inhibition of downstream signaling pathways that promote cell growth and survival. Examples of other TKIs include imatinib and erlotinib, which target specific tyrosine kinases involved in cancer.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it is not a TKI. While it may have some anticancer properties, its mechanism of action is not related to tyrosine kinase inhibition.
**Option B:** This option is incorrect because it is a different class of anticancer drug that works through a different mechanism. It is not a TKI and does not compete with ATP for binding to tyrosine kinase.
**Option C:** This option is incorrect because it is not a TKI and does not have a well-documented mechanism of action related to tyrosine kinase inhibition.
**Clinical Pearl / High-Yield Fact**
When using TKIs, it is essential to monitor for signs of myelosuppression, such as neutropenia and thrombocytopenia, as these drugs can have a significant impact on bone marrow function.
**Correct Answer:** C.